Akèy › Epatoblastòm
Etid klinik pou Epatoblastòm ap rekrite nan Etazini
11 etid pou Epatoblastòm ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Sep 1, 2026 · NCT04928677Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT04851119Molecular Basis of Pediatric Liver Cancer
Ap rekriteEtid obsèvasyon
Laj 0 a 99 · Tout sèks · Mizajou Aug 10, 2026 · NCT03959800ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Ap rekriteFaz 1/2
Laj 1 a 21 · Tout sèks · Mizajou Jul 6, 2026 · NCT04634357B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Ap rekriteFaz 1/2
12 Months – 30 Years · Tout sèks · Mizajou May 19, 2026 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Ap rekriteFaz 1
Laj 1 a 30 · Tout sèks · Mizajou Apr 15, 2026 · NCT04308330Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Mar 18, 2026 · NCT05556642Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Ap rekriteFaz 2
Laj 1 a 50 · Tout sèks · Mizajou Mar 13, 2026 · NCT01804634Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Ap rekriteFaz 1
Laj 1 a 26 · Tout sèks · Mizajou Feb 17, 2026 · NCT07148050Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou Nov 3, 2025 · NCT06198296Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.